NEWS DETAIL

  • Source : Press Release
  • Date : 2021-06-10
  • Event type : Phase 1
  • Companies : TICEBA GmbH

Epidermolysis Bullosa (EB): Orphan Drug Designation from FDA and EMA Granted

The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).